Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Vyas

Showing results (101-110 of 113) with videos related to

Pageof 12
Sort By:
Journal of Virology|February 4, 2025
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearanceTin Phan, Ruy M Ribeiro, Gregory E Edelstein, et al.
Biorxiv : the Preprint Server for Biology|September 30, 2024
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearanceTin Phan, Ruy M Ribeiro, Gregory E Edelstein, et al.
The New England Journal of Medicine|June 29, 2022
Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) InfectionJulie Boucau, Caitlin Marino, James Regan, et al.
Medrxiv : the Preprint Server for Health Sciences|March 9, 2022
Duration of viable virus shedding in SARS-CoV-2 omicron variant infectionJulie Boucau, Caitlin Marino, James Regan, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 14, 2019
CD82 controls CpG-dependent TLR9 signalingNida S Khan, Daniel P Lukason, Marianela Feliu, et al.
Journal of Dairy Science|July 22, 2020
Letter to the Editor: Silage manuscripts in the Journal of Dairy ScienceA T Adesogan, H Auerbach, T F Bernardes, et al.
JAMA Network Open|September 25, 2024
Emerging SARS-CoV-2 Resistance After Antiviral TreatmentTrevor J Tamura, Manish C Choudhary, Rinki Deo, et al.
Medrxiv : the Preprint Server for Health Sciences|March 9, 2022
Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody ResponsesMichael S Seaman, Mark J Siedner, Julie Boucau, et al.
JCI Insight|October 10, 2022
Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variantMichael S Seaman, Mark J Siedner, Julie Boucau, et al.
Research Square|December 16, 2024
Cross-neutralization of distant coronaviruses correlates with Spike S2-specific antibodies from immunocompetent and immunocompromised vaccinated SARS-CoV-2-infected patientsSara V Patel, Brooke M Leeman, Patricia J Botros, et al.
Pageof 12

Showing results (101-110 of 113) with videos related to

Sort By:
Pageof 12
Journal of Virology|February 4, 2025
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearanceTin Phan, Ruy M Ribeiro, Gregory E Edelstein, et al.
Biorxiv : the Preprint Server for Biology|September 30, 2024
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearanceTin Phan, Ruy M Ribeiro, Gregory E Edelstein, et al.
The New England Journal of Medicine|June 29, 2022
Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) InfectionJulie Boucau, Caitlin Marino, James Regan, et al.
Medrxiv : the Preprint Server for Health Sciences|March 9, 2022
Duration of viable virus shedding in SARS-CoV-2 omicron variant infectionJulie Boucau, Caitlin Marino, James Regan, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 14, 2019
CD82 controls CpG-dependent TLR9 signalingNida S Khan, Daniel P Lukason, Marianela Feliu, et al.
Journal of Dairy Science|July 22, 2020
Letter to the Editor: Silage manuscripts in the Journal of Dairy ScienceA T Adesogan, H Auerbach, T F Bernardes, et al.
JAMA Network Open|September 25, 2024
Emerging SARS-CoV-2 Resistance After Antiviral TreatmentTrevor J Tamura, Manish C Choudhary, Rinki Deo, et al.
Medrxiv : the Preprint Server for Health Sciences|March 9, 2022
Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody ResponsesMichael S Seaman, Mark J Siedner, Julie Boucau, et al.
JCI Insight|October 10, 2022
Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variantMichael S Seaman, Mark J Siedner, Julie Boucau, et al.
Research Square|December 16, 2024
Cross-neutralization of distant coronaviruses correlates with Spike S2-specific antibodies from immunocompetent and immunocompromised vaccinated SARS-CoV-2-infected patientsSara V Patel, Brooke M Leeman, Patricia J Botros, et al.
Pageof 12